This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
SGD Pharma, a global market expert in pharmaceutical glass primary packaging and sustainability, enveils its latest advancements in high-performance solutions.
SGD Pharma's IDENCYSGD Pharma
New innovations for safer, smarter pharma packaging
SGD Pharma highlights its growing portfolio of innovative glass packaging solutions designed to enhance drug integrity, patient safety and operational efficiency. Key solutions include:
· SEALIAN, a high-performance internal surface treatment that provides enhanced chemical durability and superior protection for sensitive drugs.
· IDENCY, premium vials with combined high chemical and mechanical resistance with the same outer diameter as standard tubular glass vials to ease integration into existing filing lines.
· Sterinity EZ-fill®, high-quality ready-to-use (RTU) platform enabling faster time-to-market, increased flexibility and reliability for pharma and biotech manufacturers.
· Alphial tubular products made in Italy: ampoules, vials and RTU solutions.
SGD Pharma's SterinitySGD Pharma
Alongside these product innovations, SGD Pharma offers:
- Lab Services, expertise in glass packaging science including analytical testing.
- PROSEAL+, advanced external treatment for moisture and oxygen protection.
- Velocity® vials developed with Corning to enhance fill & finish efficiency and reduce operational risks through reduced friction coating technology.
SGD Pharma's Velocity vialsSGD Pharma
Expansion into tubular glass, scaling capacity and capability with Alphial
Reflecting its strategic focus on global growth and operational excellence, SGD Pharma continues its expansion into tubular glass packaging, adding to its already global leadership in molded glass. Following the acquisition of Alphial in Q4 2025, the company now combines molded and tubular glass expertise to offer an unrivalled portfolio of solutions for customer packaging needs across ampoules, vials and RTU formats. The integration of Alphial’s Italian sites strengthens SGD Pharma’s European footprint enabling enhanced delivery speed, capacity and customer responsiveness, particularly for high-value bio-pharmaceutical applications.
Decarbonization: leading with purpose
SGD Pharma has again been awarded the EcoVadis Platinum status with a score of 90, positioning the company as the global leader of pharmaceutical glass manufacturers worldwide for sustainable performance. This recognition celebrates SGD Pharma’s unwavering commitment to environmental, social and ethical excellence across all its global sites, reaffirmed through robust governance, decarbonization initiatives, and sustainable procurement practices.
Building on its Science Based Targets initiative (SBTi)-validated roadmap, SGD Pharma is on track to achieve a 42% reduction in carbon emissions by 2030 and 65% by 2040, compared to 2022 levels. The company’s holistic sustainability strategy extends from energy efficiency investments to responsible sourcing and workforce inclusion.
Olivier Rousseau, CEO SGD Pharma, comments: “... We are proud to demonstrate how innovation and sustainability go hand in hand in shaping the future of pharmaceutical glass. As a recognized leader in sustainable glass manufacturing, we have again earned an EcoVadis platinum medal for our continued progress. We are committed to decarbonizing the Pharma Glass Industry faster than anyone else and we are working hard, and investing a lot, to do even better and go further than ever before to help our customers deliver on their own decarbonization commitments.”
